Fortress Biotech, Inc. (FBIO)
NASDAQ: FBIO · Real-Time Price · USD
2.360
+0.010 (0.43%)
At close: Apr 17, 2026, 4:00 PM EDT
2.368
+0.008 (0.33%)
After-hours: Apr 17, 2026, 5:44 PM EDT
Fortress Biotech Employees
Fortress Biotech had 101 employees as of December 31, 2024. The number of employees decreased by 85 or -45.70% compared to the previous year.
Employees
101
Change (1Y)
-85
Growth (1Y)
-45.70%
Revenue / Employee
$626,356
Profits / Employee
-$18,634
Market Cap
76.00M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 101 | -85 | -45.70% |
| Dec 31, 2023 | 186 | -1 | -0.53% |
| Dec 31, 2022 | 187 | 14 | 8.09% |
| Dec 31, 2021 | 173 | 62 | 55.86% |
| Dec 31, 2020 | 111 | 18 | 19.35% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 142 |
| Pelthos Therapeutics | 92 |
| XBiotech | 85 |
| ImmuCell | 73 |
| PMV Pharmaceuticals | 54 |
| PDS Biotechnology | 24 |
| NeurAxis | 24 |
| Alterity Therapeutics | 9 |
FBIO News
- 19 days ago - Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 20 days ago - Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million - GlobeNewsWire
- 25 days ago - Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 4 weeks ago - Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026 - GlobeNewsWire
- 7 weeks ago - UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million - GlobeNewsWire
- 7 weeks ago - Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million - GlobeNewsWire
- 7 weeks ago - Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease - GlobeNewsWire
- 3 months ago - Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States - GlobeNewsWire